



**National Agency for Food & Drug Administration &
Control (NAFDAC)**

**Registration & Regulatory Affairs (R & R)
Directorate**

**SUMMARY OF PRODUCT CHARACTERISTICS
(SmPC) TEMPLATE**

1. NAME OF THE MEDICINAL PRODUCT

REALS NIGHT AID (DIPHENHYDRAMINE TABLETS BP 50 MG)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Film Coated Tablet Contains:

Diphenhydramine Hydrochloride BP 50 mg

Excipients Q.S.

Colour: Brilliant Blue Lake & Titanium Dioxide BP

3. PHARMACEUTICAL FORM

Film Coated Tablet

FOR ORAL USE ONLY

4. Clinical particulars

4.1 Therapeutic indications

An aid to the relief of temporary sleep disturbance.

4.2 Posology and method of administration

Dosage instructions:

One tablet to be taken 20 minutes before going to bed, or as directed by a physician. Do not exceed the stated dose or frequency of dosing.

Children: Do not use in children under 16 years.

This medicinal product should not be used continuously for longer than 2 weeks without consulting a doctor.

Method of administration

For oral administration.

4.3 Contraindications

Diphenhydramine is contraindicated for patients known to be hypersensitive to the drug or to any of the excipients listed in section 6.1.

Contraindicated for use in patients with the following conditions: stenosing peptic ulcer, pyloro-duodenal obstruction.

4.4 Special warnings and precautions for use

- Diphenhydramine should be used with caution in patients with myasthenia gravis, epilepsy or seizure disorders, prostatic hypertrophy, urinary retention, narrow-angle glaucoma, asthma, bronchitis and chronic obstructive pulmonary disease (COPD), moderate to severe hepatic impairment and moderate to severe renal impairment.
- Tolerance may develop with continuous use. Seek medical advice if sleeplessness persists, as insomnia may be a symptom of a serious underlying medical illness.
- This medicinal product should not be used continuously for longer than 2 weeks without consulting a doctor.
- May increase the effects of alcohol, therefore alcohol should be avoided.
- Avoid use of other antihistamine-containing preparations, including topical antihistamines and cough and cold medicines.
- Use with caution in the elderly, who are more likely to experience side-effects. Avoid use in elderly patients with confusion.
- Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Interaction with other medicinal products and other forms of interaction: Diphenhydramine may potentiate the sedative effects of alcohol and other CNS depressants (e.g. tranquillizers, hypnotics and anxiolytics).

Monoamine oxidase inhibitors (MAOIs) prolong and intensify the anticholinergic effects of diphenhydramine. The product should be used with caution with MAOIs or within 2 weeks of stopping an MAOI.

REALS NIGHT AID		
DIPHENHYDRAMINE TABLETS BP 50 MG		
MODULE I :	ADMINISTRATIVE PARTICULARS OF THE PRODUCT	
Document	1.3	Product Information

As diphenhydramine has some antimuscarinic activity, the effects of some anticholinergic drugs (e.g. atropine, tricyclic antidepressants) may be potentiated therefore medical advice should be sought before taking diphenhydramine with such medicines.

Diphenhydramine is an inhibitor of the cytochrome p450 isoenzyme CYP2D6.

Therefore, there may be a potential for interaction with drugs which are primarily metabolised by CYP2D6, such as metoprolol and venlafaxine.

Diphenhydramine should not be used in patients receiving any of the above drugs unless directed by a doctor.

4.6 Pregnancy and Lactation

Pregnancy: Diphenhydramine crosses the placenta. Because animal reproduction studies are not always predictive of human response and since there is inadequate experience with use of diphenhydramine in pregnant women, the potential risk for humans is unknown. Use of sedating antihistamines during the third trimester may result in reactions in the newborn or premature neonates. This drug is not recommended during pregnancy. Consult a doctor before use.

Breastfeeding: Diphenhydramine has been detected in breast milk, but the effect of this on breastfed infants is unknown. Diphenhydramine is not recommended for use during breastfeeding. Consult a doctor before use.

Fertility: There are no available data on the effect of diphenhydramine on fertility.

Effects on ability to drive and use machines

Diphenhydramine is a hypnotic and will produce drowsiness or sedation soon after the dose has been taken. It may also cause dizziness, blurred vision, cognitive and psychomotor impairment. These can seriously affect the patient's ability to drive and use machines. If affected, do not drive or operate machinery.

4.7 Undesirable effects

Specific estimation of the frequency of adverse events for OTC products is inherently difficult (particularly numerator data). Adverse reactions which have been observed in clinical trials and which are considered to be common (occurring in >1/100 to <1/10) or very common (occurring in >1/10) are listed below by MedDRA System Organ Class. The frequency of other adverse reactions identified during post-marketing use is unknown, but these reactions are likely to be uncommon (occurring in >1/1000 to <1/100), or rare (occurring in <1/1000).

Blood and lymphatic system disorders:

Unknown: agranulocytosis

Immune system disorders:

Unknown: hypersensitivity reactions including rash, urticaria, dyspnoea and angioedema

Psychiatric disorders:

Unknown: confusion, paradoxical excitation (e.g. increased energy, restlessness, nervousness), depression, sleep disturbances

* The elderly are more prone to confusion and paradoxical excitation.

Nervous system disorders:

Common: sedation, drowsiness, disturbance in attention, unsteadiness, dizziness
Unknown: convulsions, headache, paraesthesia, dyskinesias

Eye disorders:

Unknown: blurred vision

REALS NIGHT AID		
DIPHENHYDRAMINE TABLETS BP 50 MG		
MODULE I :	ADMINISTRATIVE PARTICULARS OF THE PRODUCT	
Document	1.3	Product Information

Cardiac disorders:

Unknown: tachycardia, palpitations, arrhythmias

Respiratory, thoracic and mediastinal disorders:

Unknown: thickening of bronchial secretions

Gastrointestinal disorders:

Common: dry mouth

Unknown: gastrointestinal disturbance including nausea, vomiting

Musculoskeletal and connective tissue disorders:

Unknown: muscle twitching

Renal and urinary disorders:

Unknown: urinary difficulty, urinary retention

General disorders and administration site conditions:

Common: fatigue

4.8 Overdose

Overdose is likely to result in effects similar to those listed under adverse reactions. Additional symptoms may include mydriasis, fever, flushing, agitation, tremor, dystonic reactions, hallucinations and ECG changes. Large overdose may cause rhabdomyolysis, convulsions, delirium, toxic psychosis, arrhythmias, coma and cardiovascular collapse.

Treatment should be supportive and directed towards specific symptoms. Convulsions and marked CNS stimulation should be treated with parenteral diazepam.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties:

Pharmacotherapeutic classification: Antihistamines for Systemic Use – aminoalkyl ethers

ATC code: R06AA02

Diphenhydramine is an ethanolamine-derivative antihistamine. It is an antihistamine with anticholinergic and marked sedative effects. It acts by inhibiting the effects on H1-receptors.

Diphenhydramine is effective in reducing sleep onset (i.e. time to fall asleep) and increasing the depth and quality of sleep.

5.2 Pharmacokinetic Properties:

Diphenhydramine hydrochloride is rapidly absorbed following oral administration. Apparently it undergoes first-pass metabolism in the liver and only about 40-60% of an oral dose reaches systemic circulation as unchanged diphenhydramine.

It is rapidly distributed throughout the whole body. Peak plasma concentrations are attained within 1-4 hours. The sedative effect also appears to be maximal within 1-3 hours after administration of a single dose.

It is positively correlated with the plasma drug concentration.

Diphenhydramine is approx 80-85% bound to plasma proteins. Diphenhydramine is rapidly and almost completely metabolised. The drug is metabolised principally to diphenylmethoxyacetic acid and is also dealkylated.

The metabolites are conjugated with glycine and glutamine and excreted in urine. Only about 1% of a single dose is excreted unchanged in urine.

The elimination half-life ranges from 2.4-9.3 hours in healthy adults. The terminal elimination half-life is prolonged in liver cirrhosis.

REALS NIGHT AID		
DIPHENHYDRAMINE TABLETS BP 50 MG		
MODULE I :	ADMINISTRATIVE PARTICULARS OF THE PRODUCT	
Document	1.3	Product Information

5.3 Preclinical safety data:

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

List of Excipients:

Starch BP
Calcium Hydrogen Phosphate Dihydrate BP
Povidone BP
Isopropyl Alcohol BP
Sodium Starch Glycolate BP
Purified Talc BP
Colloidal Anhydrous Silica BP
Magnesium Stearate BP
Colour Coat Blue FC4SI
Silver Colour
Methylene Chloride BP

6.2 Incompatibilities : Not Applicable

6.3 Shelflife

36 months from the date of manufacturing

6.4 Special precautions for storage

Store below 30°C. Protect from light and moisture.

6.5 Nature and contents of container <and special equipment for use, administration or implantation>

2 X 15, 1 X 10 and 3 X 10 Alu-PVC Blister are packed in printed carton along with package insert.

6.6 Special precautions for disposal <and other handling>

No special requirements

7. <APPLICANT/MANUFACTURER>

REALS PHARMACEUTICALS LTD.
Reals Plaza, Plot 1, Junaid Dosunmu
Street, CBD Alausa, Ikeja, Lagos State.

